eFFECTOR Therapeutics Key Executives
This section highlights eFFECTOR Therapeutics's key executives, including their titles and compensation details.
Find Contacts at eFFECTOR Therapeutics
(Showing 0 of )
eFFECTOR Therapeutics Earnings
This section highlights eFFECTOR Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
$0.00
Stock Price
$941
Market Cap
14
Employees
Solana Beach, CA
Location
Financial Statements
Access annual & quarterly financial statements for eFFECTOR Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $- | $3.55M | $1.43M | $42.00M | $- |
| Cost of Revenue | $111.00K | $53.00K | $24.00K | $21.83M | $307.00K |
| Gross Profit | $-22.92M | $3.50M | $1.41M | $20.17M | $-307.00K |
| Gross Profit Ratio | 0.00% | 98.51% | 98.30% | 48.02% | 0.00% |
| Research and Development Expenses | $22.92M | $23.31M | $19.96M | $21.83M | $23.58M |
| General and Administrative Expenses | $10.93M | $12.64M | $13.37M | $4.35M | $4.71M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $10.93M | $12.64M | $13.37M | $4.35M | $4.71M |
| Other Expenses | $- | $-3.55M | $-1.43M | $9.00K | $- |
| Operating Expenses | $33.84M | $32.40M | $31.90M | $26.18M | $28.30M |
| Cost and Expenses | $33.84M | $32.40M | $31.90M | $26.18M | $28.61M |
| Interest Income | $1.95M | $439.00K | $6.00K | $67.00K | $239.00K |
| Interest Expense | $- | $2.25M | $1.76M | $1.33M | $1.38M |
| Depreciation and Amortization | $111.00K | $53.00K | $24.00K | $160.00K | $307.00K |
| EBITDA | $-33.73M | $-32.40M | $-31.90M | $16.05M | $-28.30M |
| EBITDA Ratio | 0.00% | -911.99% | -2230.56% | 38.23% | 0.00% |
| Operating Income | $-33.84M | $-32.40M | $-31.90M | $15.82M | $-28.61M |
| Operating Income Ratio | 0.00% | -911.99% | -2230.56% | 37.66% | 0.00% |
| Total Other Income Expenses Net | $-1.97M | $9.74M | $47.70M | $-1.26M | $-1.13M |
| Income Before Tax | $-35.81M | $-22.66M | $15.80M | $14.56M | $-29.74M |
| Income Before Tax Ratio | 0.00% | -637.91% | 1104.76% | 34.67% | 0.00% |
| Income Tax Expense | $- | $-9.74M | $-24.00K | $351.00K | $135.14K |
| Net Income | $-35.81M | $-12.93M | $15.80M | $14.21M | $-29.74M |
| Net Income Ratio | 0.00% | -363.83% | 1104.76% | 33.84% | 0.00% |
| EPS | $-16.37 | $-7.85 | $9.78 | $23.74 | $-53.83 |
| EPS Diluted | $-16.37 | $-7.85 | $9.78 | $23.74 | $-53.83 |
| Weighted Average Shares Outstanding | 2.19M | 1.65M | 1.62M | 598.56K | 552.43K |
| Weighted Average Shares Outstanding Diluted | 2.19M | 1.65M | 1.62M | 598.56K | 552.43K |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $162.00K | $- | $- | $- | $- | $- | $2.01M | $- | $1.43M | $427.00K | $692.00K | $- | $42.00K | $574.00K | $15.05M | $26.33M |
| Cost of Revenue | $28.00K | $30.00K | $26.00K | $27.00K | $- | $- | $- | $3.00K | $5.00K | $4.00K | $6.00K | $4.07M | $7.00K | $4.60M | $6.78M | $4.83M | $5.62M |
| Gross Profit | $-28.00K | $132.00K | $-26.00K | $-27.00K | $- | $- | $- | $2.01M | $-5.00K | $1.43M | $421.00K | $-3.38M | $-7.00K | $-4.56M | $-6.21M | $10.23M | $20.70M |
| Gross Profit Ratio | 0.00% | 81.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 99.90% | 0.00% | 99.70% | 98.60% | -488.40% | 0.00% | -10854.76% | -1081.18% | 67.94% | 78.64% |
| Research and Development Expenses | $5.31M | $6.04M | $5.36M | $4.88M | $6.61M | $6.65M | $6.63M | $6.92M | $3.11M | $6.39M | $5.02M | $4.07M | $4.47M | $4.60M | $6.78M | $4.83M | $5.62M |
| General and Administrative Expenses | $3.09M | $2.52M | $2.50M | $2.97M | $2.93M | $2.75M | $3.49M | $2.97M | $3.44M | $6.32M | $4.12M | $1.66M | $1.27M | $1.06M | $1.06M | $1.12M | $1.10M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $3.09M | $2.52M | $2.50M | $2.97M | $2.93M | $2.75M | $3.49M | $2.97M | $3.44M | $6.32M | $4.12M | $1.66M | $1.27M | $1.06M | $1.06M | $1.12M | $1.10M |
| Other Expenses | $- | $3.00K | $- | $-14.00K | $- | $-675.00K | $38.00K | $-2.01M | $-686.00K | $-311.00K | $290.00K | $-25.00K | $-48.00K | $77.00K | $4.00K | $- | $- |
| Operating Expenses | $8.40M | $8.57M | $7.86M | $7.86M | $9.54M | $8.72M | $9.25M | $7.88M | $6.55M | $12.40M | $8.71M | $5.04M | $5.74M | $5.66M | $7.84M | $1.19M | $1.11M |
| Cost and Expenses | $8.40M | $8.60M | $7.86M | $7.86M | $9.54M | $8.72M | $9.25M | $7.88M | $6.55M | $12.40M | $8.71M | $5.04M | $5.74M | $5.66M | $7.84M | $6.01M | $6.74M |
| Interest Income | $323.00K | $223.00K | $296.00K | $227.00K | $226.00K | $209.00K | $142.00K | $64.00K | $24.00K | $4.00K | $1.00K | $1.00K | $1.00K | $2.00K | $3.00K | $324.00K | $291.00K |
| Interest Expense | $749.00K | $758.00K | $750.00K | $722.00K | $689.00K | $697.00K | $570.00K | $505.00K | $478.00K | $490.00K | $488.00K | $480.00K | $306.00K | $314.00K | $342.00K | $- | $- |
| Depreciation and Amortization | $28.00K | $30.00K | $26.00K | $27.00K | $28.00K | $27.00K | $18.00K | $3.00K | $5.00K | $4.00K | $6.00K | $6.00K | $7.00K | $33.00K | $40.00K | $41.00K | $46.00K |
| EBITDA | $-8.37M | $-8.57M | $-7.83M | $-7.62M | $-9.30M | $-8.54M | $-9.23M | $-7.88M | $-7.21M | $-12.40M | $-8.42M | $-5.04M | $-5.73M | $-5.51M | $-7.23M | $9.14M | $19.65M |
| EBITDA Ratio | 0.00% | -5288.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -382.45% | 0.00% | -867.34% | -1971.19% | -732.37% | 0.00% | -13111.90% | -1265.16% | 60.74% | 74.63% |
| Operating Income | $-8.40M | $-8.60M | $-8.30M | $-7.86M | $-9.54M | $-8.72M | $-9.25M | $-7.88M | $-6.55M | $20.03M | $-8.71M | $-5.04M | $-5.74M | $-5.62M | $-7.27M | $9.10M | $19.60M |
| Operating Income Ratio | 0.00% | -5306.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -391.89% | 0.00% | 1400.63% | -2040.75% | -728.90% | 0.00% | -13378.57% | -1266.38% | 60.47% | 74.45% |
| Total Other Income Expenses Net | $-438.00K | $-532.00K | $-448.00K | $-509.00K | $-478.00K | $-537.00K | $-308.00K | $966.00K | $9.62M | $31.45M | $17.59M | $-504.00K | $-845.00K | $-235.00K | $-335.00K | $-385.00K | $-302.00K |
| Income Before Tax | $-8.83M | $-9.13M | $-8.30M | $-8.36M | $-10.01M | $-9.26M | $-9.56M | $-6.92M | $3.07M | $19.05M | $8.88M | $-5.55M | $-6.58M | $-5.85M | $-7.60M | $8.72M | $19.30M |
| Income Before Tax Ratio | 0.00% | -5635.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -343.86% | 0.00% | 1332.10% | 2079.39% | -801.73% | 0.00% | -13938.10% | -1324.74% | 57.91% | 73.31% |
| Income Tax Expense | $- | $-688.00K | $-20.00K | $708.00K | $- | $- | $608.00K | $187.00K | $-662.00K | $-32.44M | $778.00K | $449.00K | $258.00K | $-5.07M | $5.00K | $126.00K | $220.00K |
| Net Income | $-8.83M | $-9.13M | $-8.30M | $-8.36M | $-10.01M | $-9.26M | $-9.56M | $-6.92M | $3.07M | $19.05M | $8.88M | $-5.55M | $-6.58M | $-397.00K | $-7.61M | $7.44M | $736.00K |
| Net Income Ratio | 0.00% | -5635.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -343.86% | 0.00% | 1332.10% | 2079.39% | -801.73% | 0.00% | -945.24% | -1325.61% | 49.39% | 2.80% |
| EPS | $-2.16 | $-3.42 | $-3.36 | $-4.37 | $-5.96 | $-5.57 | $-5.80 | $-4.20 | $1.77 | $11.79 | $5.50 | $-6.15 | $-11.00 | $-0.66 | $-12.71 | $134.79 | $13.34 |
| EPS Diluted | $-2.16 | $-3.42 | $-3.36 | $-4.37 | $-5.96 | $-5.57 | $-5.80 | $-4.20 | $1.77 | $11.79 | $5.50 | $-6.15 | $-11.00 | $-0.66 | $-12.71 | $134.79 | $13.34 |
| Weighted Average Shares Outstanding | 4.08M | 2.67M | 2.47M | 1.91M | 1.68M | 1.66M | 1.65M | 1.64M | 1.74M | 1.62M | 1.61M | 902.25K | 598.56K | 598.56K | 598.56K | 55.17K | 55.17K |
| Weighted Average Shares Outstanding Diluted | 4.08M | 2.67M | 2.47M | 1.91M | 1.68M | 1.66M | 1.65M | 1.64M | 1.74M | 1.62M | 1.61M | 902.25K | 598.56K | 598.56K | 598.56K | 55.17K | 55.17K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $14.88M | $8.71M | $49.70M | $15.22M | $3.43M |
| Short Term Investments | $3.50M | $17.60M | $- | $- | $- |
| Cash and Short Term Investments | $18.37M | $26.31M | $49.70M | $15.22M | $3.43M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $-27.00K | $-100.00K | $- | $- |
| Other Current Assets | $1.47M | $1.70M | $6.39M | $2.72M | $845.00K |
| Total Current Assets | $19.84M | $28.01M | $52.90M | $16.58M | $4.27M |
| Property Plant Equipment Net | $193.00K | $352.00K | $257.00K | $126.00K | $823.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $513.00K | $711.00K | $903.00K | $-126.00K | $-823.00K |
| Total Non-Current Assets | $706.00K | $1.06M | $1.16M | $126.00K | $823.00K |
| Other Assets | $- | $- | $- | $- | $1 |
| Total Assets | $20.54M | $29.08M | $54.06M | $16.70M | $5.09M |
| Account Payables | $2.33M | $1.49M | $516.00K | $347.00K | $598.00K |
| Short Term Debt | $20.55M | $20.22M | $88.00K | $6.01M | $15.24M |
| Tax Payables | $- | $463.00K | $351.00K | $351.00K | $- |
| Deferred Revenue | $- | $- | $- | $1.98M | $- |
| Other Current Liabilities | $2.92M | $2.90M | $3.02M | $2.07M | $3.09M |
| Total Current Liabilities | $25.80M | $25.07M | $3.98M | $8.78M | $18.93M |
| Long Term Debt | $- | $120.00K | $19.99M | $6.95M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $543.00K | $-14.00K | $12.81M | $133.22M | $- |
| Total Non-Current Liabilities | $543.00K | $106.00K | $32.79M | $140.17M | $- |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $26.34M | $25.18M | $36.77M | $148.95M | $18.93M |
| Preferred Stock | $- | $- | $54.06M | $133.22M | $133.22M |
| Common Stock | $- | $4.00K | $4.00K | $1.00K | $1.00K |
| Retained Earnings | $-179.38M | $-143.57M | $-120.90M | $-136.70M | $-150.91M |
| Accumulated Other Comprehensive Income Loss | $- | $-18.00K | $-54.06M | $-133.22M | $-999 |
| Other Total Stockholders Equity | $173.58M | $147.48M | $192.24M | $137.68M | $3.85M |
| Total Stockholders Equity | $-5.79M | $3.90M | $17.28M | $-132.25M | $-13.84M |
| Total Equity | $-5.79M | $3.90M | $17.28M | $-132.25M | $-13.84M |
| Total Liabilities and Stockholders Equity | $20.54M | $29.08M | $54.06M | $16.70M | $5.09M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $20.54M | $29.08M | $54.06M | $16.70M | $5.09M |
| Total Investments | $3.50M | $17.60M | $- | $- | $- |
| Total Debt | $20.55M | $20.28M | $20.03M | $12.96M | $15.24M |
| Net Debt | $5.67M | $11.57M | $-29.67M | $-2.25M | $11.82M |
Balance Sheet Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $15.51M | $14.88M | $5.39M | $14.71M | $10.31M | $8.71M | $11.90M | $16.35M | $17.66M | $49.70M | $54.77M | $10.88M | $16.77M | $15.22M | $-3.43M |
| Short Term Investments | $9.88M | $3.50M | $12.39M | $10.30M | $8.70M | $17.60M | $21.05M | $24.68M | $28.04M | $- | $- | $- | $- | $- | $6.85M |
| Cash and Short Term Investments | $25.38M | $18.37M | $17.78M | $25.02M | $19.01M | $26.31M | $32.96M | $41.04M | $45.71M | $49.70M | $54.77M | $10.88M | $16.77M | $15.22M | $3.43M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $500.00K | $1.40M | $- | $- |
| Inventory | $- | $- | $-23.00K | $-72.00K | $- | $- | $-400.00K | $-400.00K | $- | $-100.00K | $-200.00K | $1 | $- | $- | $- |
| Other Current Assets | $867.00K | $1.47M | $1.50M | $956.00K | $1.89M | $1.70M | $2.56M | $2.49M | $5.27M | $6.39M | $4.17M | $654.00K | $-1.18M | $1.36M | $- |
| Total Current Assets | $26.25M | $19.84M | $19.28M | $25.98M | $20.89M | $28.01M | $35.52M | $42.28M | $48.34M | $52.90M | $58.94M | $12.03M | $17.00M | $16.58M | $3.43M |
| Property Plant Equipment Net | $415.00K | $193.00K | $312.00K | $299.00K | $311.00K | $352.00K | $371.00K | $381.00K | $302.00K | $257.00K | $45.00K | $68.00K | $97.00K | $126.00K | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $175.01M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $466.00K | $513.00K | $567.00K | $615.00K | $723.00K | $711.00K | $759.00K | $807.00K | $854.00K | $903.00K | $950.00K | $-172.83M | $56.00K | $- | $-3.43M |
| Total Non-Current Assets | $881.00K | $706.00K | $879.00K | $914.00K | $1.03M | $1.06M | $1.13M | $1.19M | $1.16M | $1.16M | $995.00K | $2.25M | $153.00K | $126.00K | $-3.43M |
| Other Assets | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- |
| Total Assets | $27.13M | $20.54M | $20.16M | $26.89M | $21.93M | $29.08M | $36.65M | $43.47M | $49.49M | $54.06M | $59.94M | $14.28M | $17.15M | $16.70M | $- |
| Account Payables | $1.71M | $2.33M | $1.14M | $1.45M | $3.79M | $1.49M | $1.21M | $1.20M | $294.00K | $516.00K | $321.00K | $1.91M | $458.00K | $347.00K | $- |
| Short Term Debt | $20.07M | $20.55M | $20.47M | $20.39M | $20.30M | $20.22M | $20.14M | $20.06M | $92.00K | $88.00K | $56.00K | $55.00K | $18.56M | $6.01M | $- |
| Tax Payables | $- | $- | $- | $- | $473.00K | $463.00K | $351.00K | $351.00K | $351.00K | $351.00K | $351.00K | $351.00K | $351.00K | $351.00K | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $-54.00K | $- | $- | $- | $2.75M | $2.66M | $351.00K | $1.98M | $- |
| Other Current Liabilities | $3.79M | $2.92M | $1.98M | $1.92M | $2.08M | $2.90M | $3.26M | $1.97M | $1.89M | $3.02M | $45.62M | $429.00K | $2.85M | $2.07M | $- |
| Total Current Liabilities | $25.57M | $25.80M | $23.59M | $23.76M | $26.65M | $25.07M | $24.97M | $23.59M | $2.63M | $3.98M | $46.35M | $5.40M | $22.57M | $8.78M | $- |
| Long Term Debt | $179.00K | $- | $12.00K | $50.00K | $43.00K | $60.00K | $154.00K | $188.00K | $20.02M | $19.99M | $19.76M | $19.67M | $- | $6.95M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $556.00K | $543.00K | $527.00K | $505.00K | $46.00K | $46.00K | $-31.00K | $75.00K | $1.61M | $12.81M | $1.50M | $133.22M | $- | $133.22M | $- |
| Total Non-Current Liabilities | $735.00K | $543.00K | $539.00K | $555.00K | $89.00K | $106.00K | $123.00K | $263.00K | $21.63M | $32.79M | $21.26M | $152.89M | $10.24M | $140.17M | $- |
| Other Liabilities | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-10.24M | $- | $- |
| Total Liabilities | $26.30M | $26.34M | $24.13M | $24.31M | $26.74M | $25.18M | $25.09M | $23.85M | $24.26M | $36.77M | $67.61M | $158.29M | $22.57M | $148.95M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $59.94M | $133.22M | $133.22M | $133.22M | $133.22M |
| Common Stock | $- | $- | $6.00K | $6.00K | $4.00K | $- | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $2.00K | $1.00K | $454 | $- |
| Retained Earnings | $-188.21M | $-179.38M | $-170.25M | $-161.94M | $-153.58M | $-143.57M | $-134.31M | $-124.75M | $-117.83M | $-120.90M | $-139.95M | $-148.83M | $-143.28M | $-136.70M | $- |
| Accumulated Other Comprehensive Income Loss | $- | $0 | $-1.00K | $1.00K | $1.00K | $-18.00K | $-69.00K | $-82.00K | $-50.00K | $-0 | $-59.94M | $-133.22M | $-999 | $-133.22M | $-147.06M |
| Other Total Stockholders Equity | $189.04M | $173.58M | $166.28M | $164.51M | $148.76M | $147.48M | $145.93M | $144.45M | $143.11M | $- | $132.28M | $4.82M | $4.64M | $137.68M | $1 |
| Total Stockholders Equity | $827.00K | $-5.79M | $-3.97M | $2.58M | $-4.81M | $3.90M | $11.56M | $19.62M | $25.23M | $17.28M | $-7.67M | $-144.01M | $-5.42M | $-132.25M | $-13.84M |
| Total Equity | $827.00K | $-5.79M | $-3.97M | $2.58M | $-4.81M | $3.90M | $11.56M | $19.62M | $25.23M | $17.28M | $-7.67M | $-144.01M | $-5.42M | $-132.25M | $-13.84M |
| Total Liabilities and Stockholders Equity | $27.13M | $20.54M | $20.16M | $26.89M | $21.93M | $29.08M | $36.65M | $43.47M | $49.49M | $54.06M | $59.94M | $14.28M | $17.15M | $16.70M | $-13.84M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $27.13M | $20.54M | $20.16M | $26.89M | $21.93M | $29.08M | $36.65M | $43.47M | $49.49M | $54.06M | $59.94M | $14.28M | $17.15M | $16.70M | $-13.84M |
| Total Investments | $9.88M | $3.50M | $12.39M | $10.30M | $8.70M | $17.60M | $21.05M | $24.68M | $28.04M | $- | $- | $175.01M | $- | $- | $6.85M |
| Total Debt | $20.25M | $19.45M | $20.48M | $20.41M | $20.35M | $20.28M | $20.22M | $20.15M | $20.07M | $20.03M | $19.79M | $19.72M | $18.56M | $12.96M | $- |
| Net Debt | $4.74M | $4.57M | $15.09M | $5.70M | $10.04M | $11.57M | $8.31M | $3.80M | $2.41M | $-29.67M | $-34.98M | $8.84M | $1.78M | $-2.25M | $3.43M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-35.81M | $-22.66M | $15.80M | $14.21M | $-29.74M |
| Depreciation and Amortization | $111.00K | $53.00K | $24.00K | $160.00K | $307.00K |
| Deferred Income Tax | $- | $- | $-539.00K | $-333.00K | $-1.99M |
| Stock Based Compensation | $4.59M | $5.33M | $8.66M | $499.00K | $646.00K |
| Change in Working Capital | $1.69M | $2.68M | $-238.00K | $-824.00K | $1.07M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $855.00K | $958.00K | $155.00K | $-251.00K | $-727.00K |
| Other Working Capital | $830.00K | $1.72M | $-393.00K | $-573.00K | $1.80M |
| Other Non Cash Items | $-130.00K | $-11.30M | $-48.59M | $122.00K | $2.10M |
| Net Cash Provided by Operating Activities | $-29.55M | $-25.90M | $-24.89M | $13.84M | $-27.60M |
| Investments in Property Plant and Equipment | $-97.00K | $-192.00K | $-42.00K | $-154.00K | $-4.00K |
| Acquisitions Net | $- | $17.67M | $607.00K | $- | $88.00K |
| Purchases of Investments | $-17.17M | $-52.42M | $- | $- | $- |
| Sales Maturities of Investments | $31.75M | $34.75M | $- | $- | $- |
| Other Investing Activities | $- | $-17.67M | $607.00K | $- | $88.00K |
| Net Cash Used for Investing Activities | $14.48M | $-17.86M | $565.00K | $-154.00K | $84.00K |
| Debt Repayment | $- | $- | $5.89M | $-2.00M | $- |
| Common Stock Issued | $21.18M | $2.80M | $56.00K | $108.00K | $20.33M |
| Common Stock Repurchased | $- | $- | $- | $- | $-86.00K |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $56.00K | $-34.00K | $52.91M | $108.00K | $20.24M |
| Net Cash Used Provided by Financing Activities | $21.23M | $2.77M | $58.81M | $-1.89M | $20.24M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $10.70M |
| Net Change in Cash | $6.17M | $-40.99M | $34.49M | $11.79M | $3.43M |
| Cash at End of Period | $14.88M | $8.71M | $49.70M | $15.22M | $3.43M |
| Cash at Beginning of Period | $8.71M | $49.70M | $15.22M | $3.43M | $- |
| Operating Cash Flow | $-29.55M | $-25.90M | $-24.89M | $13.84M | $-27.60M |
| Capital Expenditure | $-97.00K | $-192.00K | $-42.00K | $-154.00K | $-4.00K |
| Free Cash Flow | $-29.65M | $-26.09M | $-24.93M | $13.68M | $-27.60M |
Cash Flow Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-8.83M | $-9.13M | $-8.30M | $-8.36M | $-10.01M | $-9.26M | $-9.56M | $-6.92M | $3.07M | $19.05M | $8.88M | $-5.55M | $-6.58M | $-5.85M | $-7.61M | $26.94M | $736.00K |
| Depreciation and Amortization | $28.00K | $30.00K | $26.00K | $27.00K | $28.00K | $27.00K | $18.00K | $3.00K | $5.00K | $5.00K | $6.00K | $6.00K | $7.00K | $33.00K | $40.00K | $41.00K | $46.00K |
| Deferred Income Tax | $- | $63.00K | $-175.00K | $-78.00K | $- | $- | $- | $- | $- | $- | $-289.00K | $27.00K | $541.00K | $-401.00K | $- | $- | $- |
| Stock Based Compensation | $1.01M | $1.12M | $1.14M | $1.16M | $1.17M | $1.39M | $1.57M | $1.24M | $1.14M | $5.93M | $2.38M | $161.00K | $188.00K | $155.00K | $200.00K | $55.00K | $89.00K |
| Change in Working Capital | $479.00K | $2.43M | $-521.00K | $-1.43M | $1.21M | $1.13M | $-141.00K | $2.47M | $-780.00K | $1.85M | $-2.35M | $-553.00K | $813.00K | $-1.43M | $126.00K | $2.54M | $-2.66M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-716.00K | $1.25M | $-332.00K | $-2.29M | $2.23M | $323.00K | $-27.00K | $885.00K | $-223.00K | $181.00K | $-144.00K | $7.00K | $111.00K | $-811.00K | $- | $- | $- |
| Other Working Capital | $1.20M | $1.18M | $-189.00K | $853.00K | $-1.01M | $803.00K | $3.00K | $1.59M | $-557.00K | $1.67M | $-2.21M | $-560.00K | $702.00K | $-618.00K | $126.00K | $2.54M | $-2.66M |
| Other Non Cash Items | $39.00K | $-82.00K | $76.00K | $93.00K | $-28.00K | $-59.00K | $-8.00K | $-1.24M | $-9.93M | $-31.84M | $-17.70M | $91.00K | $36.00K | $29.00K | $-172.00K | $-17.59M | $18.53M |
| Net Cash Provided by Operating Activities | $-7.28M | $-5.57M | $-7.75M | $-8.59M | $-7.64M | $-6.78M | $-8.18M | $-4.44M | $-6.50M | $-5.01M | $-9.07M | $-5.82M | $-5.00M | $-7.47M | $-7.42M | $11.98M | $16.74M |
| Investments in Property Plant and Equipment | $- | $-54.00K | $-2.00K | $-28.00K | $-13.00K | $-13.00K | $-45.00K | $-77.00K | $-57.00K | $-36.00K | $-6.00K | $- | $- | $-154.00K | $- | $- | $- |
| Acquisitions Net | $- | $5.58M | $1.91M | $1.55M | $- | $- | $- | $-10.00M | $- | $- | $607.00K | $-607.00K | $607.00K | $- | $- | $- | $- |
| Purchases of Investments | $-9.82M | $- | $-3.91M | $-10.30M | $-2.96M | $-5.62M | $-11.83M | $-6.75M | $-28.22M | $- | $175.00M | $-175.00M | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $3.50M | $9.00M | $2.00M | $8.75M | $12.00M | $9.25M | $15.50M | $10.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $9.00M | $-1.91M | $-1.55M | $- | $- | $3.67M | $10.00M | $-28.22M | $- | $- | $- | $607.00K | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-6.32M | $8.95M | $-1.92M | $-1.57M | $9.03M | $3.62M | $3.62M | $3.17M | $-28.27M | $-36.00K | $-6.00K | $-175.61M | $607.00K | $-154.00K | $- | $- | $- |
| Debt Repayment | $-556.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-54.00K | $5.95M | $-1.50M | $- | $- | $- |
| Common Stock Issued | $14.79M | $6.11M | $324.00K | $14.53M | $212.00K | $-37.00K | $111.00K | $-42.00K | $2.77M | $-22.00K | $-16.00K | $16.00K | $177.39M | $25.00K | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-22.00K | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.00K | $- | $18.00K | $38.00K | $- | $- | $- | $- | $-34.00K | $-22.00K | $52.98M | $-40.00K | $-1.00K | $- | $-481.00K | $73.00K | $16.00K |
| Net Cash Used Provided by Financing Activities | $14.23M | $6.11M | $342.00K | $14.57M | $212.00K | $-37.00K | $111.00K | $-42.00K | $2.73M | $-22.00K | $52.96M | $-78.00K | $5.95M | $-1.50M | $-481.00K | $73.00K | $16.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.15M | $- | $-102.31K | $- | $- | $- | $- |
| Net Change in Cash | $633.00K | $9.49M | $-9.33M | $4.40M | $1.60M | $-3.19M | $-4.45M | $-1.31M | $-32.04M | $-5.07M | $43.89M | $-5.89M | $1.56M | $-9.12M | $-7.90M | $12.05M | $16.75M |
| Cash at End of Period | $15.51M | $14.88M | $5.39M | $14.71M | $10.31M | $8.71M | $11.90M | $16.35M | $17.66M | $49.70M | $54.77M | $10.88M | $16.77M | $15.22M | $24.34M | $32.23M | $20.18M |
| Cash at Beginning of Period | $14.88M | $5.39M | $14.71M | $10.31M | $8.71M | $11.90M | $16.35M | $17.66M | $49.70M | $54.77M | $10.88M | $16.77M | $15.22M | $24.34M | $32.23M | $20.18M | $3.43M |
| Operating Cash Flow | $-7.28M | $-5.57M | $-7.75M | $-8.59M | $-7.64M | $-6.78M | $-8.18M | $-4.44M | $-6.50M | $-5.01M | $-9.07M | $-5.82M | $-5.00M | $-7.47M | $-7.42M | $11.98M | $16.74M |
| Capital Expenditure | $- | $-54.00K | $-2.00K | $-28.00K | $-13.00K | $-13.00K | $-45.00K | $-77.00K | $-57.00K | $-36.00K | $-6.00K | $- | $- | $-154.00K | $- | $- | $- |
| Free Cash Flow | $-7.28M | $-5.62M | $-7.76M | $-8.62M | $-7.65M | $-6.79M | $-8.23M | $-4.51M | $-6.55M | $-5.04M | $-9.07M | $-5.82M | $-5.00M | $-7.62M | $-7.42M | $11.98M | $16.74M |
eFFECTOR Therapeutics Dividends
Explore eFFECTOR Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
eFFECTOR Therapeutics News
Read the latest news about eFFECTOR Therapeutics, including recent articles, headlines, and updates.
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed as an independent director effective on 1 December, 2024. Stephen Van Deventer, CEO of BioGene, commented: "We are excited to welcome Dr. Brian Gallagher, Jr. to our Corporate Advisory Board.
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
As the stock market hits new highs in July, investors are riding a wave of optimism, closely tracking climbing indexes. Yet, beneath this bullish surface, some publicly traded companies are becoming bankruptcy risk stocks as they're grappling with the stark reality of financial distress.
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a delisting of its securities and expects its securities to be delisted in the near term.
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer and low grade serous ovarian cancer at the Dana-Farber Cancer Institute (DFCI) under the direction of Panagiotis Konstantinopoulos, M.D., Ph.D., Director of Translational Research and attending oncologist in the Division of Gynecologic Oncology at DFCI, and an Associate Professor of Medicine at Harvard Medical School.
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif.
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16th at 11:30 am ET.
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 ≥50%. Based on 36 events, the hazard ratio for progression free survival (PFS, the primary endpoint of the study) using a stratified Cox proportional hazards model was 0.62 (95% confidence intervals 0.3 to 1.3) in favor of tomivosertib. The two-sided p value for PFS, based on a stratified log rank test, was 0.21, which did not meet the pre-specified threshold of p≤0.2. The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the placebo plus pembrolizumab arm, respectively. Overall survival results remain immature, however no trend favoring tomivosertib was observed. There were 67% Grade 3 or higher treatment emergent adverse events in the tomivosertib plus pembrolizumab arm versus 37% in the placebo plus pembrolizumab arm.
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET.
Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 814.5% in eFFECTOR Therapeutics, Inc. (EFTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it has closed its previously announced registered direct offering with a new healthcare focused institutional investor for the purchase and sale of an aggregate of 1,488,834 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 1,488,834 shares of its common stock at an offering price of $10.075 per share of common stock (or common stock equivalent in lieu thereof) and accompanying short-term warrant priced at-the-market under Nasdaq rules. The short-term warrants are exercisable immediately upon issuance, have an exercise price of $9.95 per share and expire three and one-half years from the date of issuance.
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the purchase and sale of an aggregate of 1,488,834 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 1,488,834 shares of its common stock at an offering price of $10.075 per share of common stock (or common stock equivalent in lieu thereof) and accompanying warrant, in a registered direct offering priced at-the-market under Nasdaq rules. The warrants will be exercisable immediately upon issuance, have an exercise price of $9.95 per share and expire three and one half years from the date of issuance. The closing of the offering is expected to occur on or about January 29, 2024, subject to the satisfaction of customary closing conditions.
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
- Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- - Review of recently announced interim data from dose escalation and Phase 2 expansion cohorts of zotatifin in ER+ metastatic breast cancer patients- - Webinar to take place on Wednesday, January 24, 2024, at 4:30 pm ET- SOLANA BEACH, Calif. and REDWOOD CITY, Calif.
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
Designation is for 2 nd or 3 rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor
eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a poster presentation of new clinical data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC) at the San Antonio Breast Cancer Symposium 2023 Annual Meeting, taking place from December 5 – 9, 2023 in San Antonio, Texas. eFFECTOR plans to discuss the results of the clinical trial and provide further updates on zotatifin development at the conference. Presentation details can be found below.
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Management intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium (SABCS)
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will participate in a fireside chat discussion and host 1x1 meetings at the 2023 Stifel Healthcare Conference taking place November 14-15, 2023 in New York, NY.
eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia
Trial designed to capitalize on previously published results that showed preclinical activity of tomivosertib in AML models Trial designed to capitalize on previously published results that showed preclinical activity of tomivosertib in AML models
3 Promising Biotech Stocks That Will Make Early Investors Rich
For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeutic innovations that could change paradigms for patient care.
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board's Audit Committee. Concurrent with Ms. Loewy's appointment, current Board member John Smither has resigned from the Board.
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences:
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding better ways to use the stock market to capture gains.
7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?
Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing possibility of significant returns.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for EFTR.